Skip to content

A Study on the Efficacy and Safety of Saccharomyces boulardii Powder Combined with Triple Therapy in HP-Related Peptic Ulcers

A Study on the Efficacy and Safety of Saccharomyces boulardii Powder Combined with Triple Therapy in HP-Related Peptic Ulcers

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111294
Enrollment
Unknown
Registered
2025-10-29
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HelicobaHelicobacter pylori-related peptic ulcercter pylori-related gastric ulcer

Interventions

Experimental group:Saccharomyces boulardii Sachets + Standard triple therapy

Sponsors

Affiliated Hospital of Guangdong Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age 18–70, no gender restrictions; 2. Confirmed as a peptic ulcer via gastroscopy; 3. Positive Hp detection (rapid urease test/¹³C-UBT/pathological biopsy); 4. Not treated with HP eradication therapy; 5. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Use of antibiotics/probiotics within the past month; 2. Severe hepatic or renal impairment, pregnancy, or immunodeficiency; 3. Research on drug allergies; 4. A history of prior gastric surgery; 5. Researchers deemed the subject ineligible for inclusion.

Design outcomes

Primary

MeasureTime frame
HP eradication rate;

Secondary

MeasureTime frame
Time to symptom relief (abdominal pain, bloating) (in days);Ulcer healing rate;Incidence of adverse reactions (diarrhea, nausea, rash);

Countries

China

Contacts

Public ContactYe Shicai

Affiliated Hospital of Guangdong Medical University

caizi23@126.com+86 135 9004 2925

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026